Insulet

PODD

Market cap $17.4B

The market is overstating the impact of GLP-1s and fails to recognize that GLP-1s pose no direct threat to Insulet's customer base. International expansion into Europe (the largest addressable market for T1D) and the shift into MENA focus will drive top-line growth. The T2D market is underpenetrated, representing a wide potential runway, from which PODD is set to win the most based on structural moats.

Insulet Q4 Earnings Review: Strong Performance Meets Sky-High Expectations

Insulet jumps after Q4 EPS and revenue beat, margin expansion and record Omnipod growth power a strong 2025 finish and upbeat 2026 outlook.

Insulet Corporation (PODD) Q4 2025 Earnings Call Transcript

Insulet Corporation  (NASDAQ: PODD) stock is trading higher on Wednesday after the company reported better-than-expected fourth-quarter earnings and 2026 guidance.

The headline numbers for Insulet (PODD) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Insulet (PODD) came out with quarterly earnings of $1.55 per share, beating the Zacks Consensus Estimate of $1.48 per share. This compares to earnings of $1.15 per share a year ago.

Insulet reported better-than-expected fourth-quarter results on Wednesday, on the back of strong demand for its tubeless insulin pumps that eliminate the need for daily injections.

ACTON, Mass.--(BUSINESS WIRE)--Insulet Reports Fourth Quarter and Full Year 2025 Results.

Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Insulet (PODD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2025.